Nanjing Leads Biolabs Co., Ltd.
- Country
- 🇨🇳China
- Ownership
- Holding, Subsidiary
- Established
- 2012-11-27
- Employees
- 1
- Market Cap
- -
- Website
- http://leadsbiolabs.com
Clinical Trials
12
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (12 trials with phase data)• Click on a phase to view related trials
A Phase Ib/Ⅱ Trial of LBL-024 in Combination With Paclitaxel in Patients With Platinum-resistant Ovarian Cancer
- Conditions
- Ovarian Cancer
- Interventions
- Drug: LBL-024 Injection
- First Posted Date
- 2025-06-29
- Last Posted Date
- 2025-06-29
- Lead Sponsor
- Nanjing Leads Biolabs Co.,Ltd
- Target Recruit Count
- 110
- Registration Number
- NCT07042802
A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 01(NSCLC)]
- Conditions
- Advanced Solid Tumour
- Interventions
- First Posted Date
- 2025-01-20
- Last Posted Date
- 2025-07-10
- Lead Sponsor
- Nanjing Leads Biolabs Co.,Ltd
- Target Recruit Count
- 210
- Registration Number
- NCT06783647
- Locations
- 🇨🇳
Fujian Cancer Hospital, Fuzhou, Fujian, China
🇨🇳Guangxi Medical University Cancer Hospital, Nanning, Guangxi, China
🇨🇳Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China
A Clinical Trial of LBL-024 Combined With Etoposide and Platinum in Patients With Advanced Neuroendocrine Carcinoma
- Conditions
- Advanced Neuroendocrine Carcinoma
- Interventions
- First Posted Date
- 2023-12-06
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Nanjing Leads Biolabs Co.,Ltd
- Target Recruit Count
- 178
- Registration Number
- NCT06157827
- Locations
- 🇨🇳
Anhui Provincial Hospital, Hefei, Anhui, China
🇨🇳Anhui Cancer Hospital, Hefei, Anhui, China
🇨🇳Beijing GoBroad Hospital, Beijing, Beijing, China
A Phase I/II Clinical Trial of LBL-034 in Patients With Relapsed Refractory Multiple Myeloma
- Conditions
- Relapsed/Refractory Multiple Myeloma
- Interventions
- Drug: LBL-034 for Injection
- First Posted Date
- 2023-09-22
- Last Posted Date
- 2025-06-03
- Lead Sponsor
- Nanjing Leads Biolabs Co.,Ltd
- Target Recruit Count
- 342
- Registration Number
- NCT06049290
- Locations
- 🇨🇳
The First Affiliated Hospital of Wannan Medical College, Wuhu, Anhui, China
🇨🇳Peking University People's Hospital, Beijing, Beijing, China
🇨🇳Peking University Shougang Hospital, Beijing, Beijing, China
A Phase I/II Clinical Trial of LBL-033 in the Treatment of Advanced Malignant Tumors
- Conditions
- Advanced Malignant Tumors
- Interventions
- Drug: LBL-033 for Injection
- First Posted Date
- 2023-03-22
- Last Posted Date
- 2025-05-07
- Lead Sponsor
- Nanjing Leads Biolabs Co.,Ltd
- Target Recruit Count
- 468
- Registration Number
- NCT05779163
- Locations
- 🇨🇳
Fujian Cancer Hospital, Fuzhou, Fujian, China
🇨🇳Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
🇨🇳Henan Cancer Hospital, Zhengzhou, Henan, China
- Prev
- 1
- 2
- 3
- Next
News
LBL-024 Bispecific Antibody Shows 75% Response Rate in Advanced Neuroendocrine Carcinoma Trial
Leads Biolabs' LBL-024, a first-in-class PD-L1/4-1BB bispecific antibody, achieved a 75% overall response rate in 52 patients with advanced extrapulmonary neuroendocrine carcinoma when combined with chemotherapy.